Press Releases

ARUP is using Deep Bio’s artificial intelligence-based software in research to evaluate how use of the software may aid in detection and classification of prostate cancer cells, such as the cells pictured here.

A donor collection specialist at the ARUP Blood Services Donor Center in Sandy bandages a donor’s arm after she has finished donating blood. ARUP is seeking donations of O-positive and O-negative blood to help address a critical shortage.

President and Chief Medical Officer Tracy George, MD, worked with ARUP’s PharmaDX and Clinical Trials group to create the central pathology review offering used in clinical trials for AYVAKIT. The new precision therapy for advanced systemic mastocytosis recently earned approval from the U.S. Food and Drug Administration.

Adam Barker, PhD, has been named ARUP’s first chief scientific officer. He moves into the role after having spent four years as director of Research and Development.

New Infectious Diseases Society of America guidelines, authored by a panel led by ARUP’s Kimberly Hanson, MD, MHS, describe the benefits and limitations of COVID-19 rapid antigen testing. The expert panel suggests that standard nucleic acid amplification testing should be used instead of rapid antigen tests in most circumstances when possible.

ARUP Chief Operations Officer Jonathan Genzen, MD, PhD (left), joined CEO Sherrie L. Perkins, MD, PhD, President Andy Theurer, and Board Chairman Peter Jensen, MD, on June 15, 2021, to cut a ceremonial ribbon to officially open ARUP’s new state-of-the-art laboratory facility in University of Utah Research Park.

The NanoSpot.AI rapid COVID-19 antibody test is performed on blood collected through a finger prick using a microcollection tube. Droplets of blood are then placed on three spots on a ready-to-use, synthetic, embossed card. One of the spots displays the test result.

CEO Sherrie L. Perkins, MD, PhD (left), has announced her retirement effective June 30, 2021, and President Andy Theurer (center) has been appointed to replace her as CEO. Tracy I. George, MD (right), will replace Theurer as president and will also retain her current position as chief medical officer.